Search

everythinglearnresearchcommunity

for

Search:↓

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.

Mogamulizumab, a skin cancer drug, may cause hair loss similar to alopecia areata.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

Infliximab was effective in treating a scalp condition that did not respond to other treatments.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

Tocilizumab might be an effective treatment for COVID-19.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Ustekinumab effectively treated psoriasis and ulcerative colitis in a teen after infliximab caused complications.

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.

Upadacitinib improved multiple immune-related conditions in one patient.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.